Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection for Early-Stage Breast Cancer and Sentinel Lymph Node Metastasis: An Updated Systematic Review and Meta-Analysis With Special Focus on Locoregional Recurrence and Regional Node Irradiation

Abstract

Background:

The management of early breast cancer patients with metastatic sentinel lymph nodes (SLNs) remains a critical decision point in balancing survival outcomes with surgical morbidities. This study addresses whether sentinel lymph node biopsy (SLNB) with or without regional node irradiation (RNI) can offer comparable survival outcomes to axillary lymph node dissection (ALND).

Objectives:

To evaluate overall survival (OS), disease-free survival (DFS), locoregional recurrence (LRR), and mortality outcomes of SLNB (with or without RNI) compared with ALND in patients with metastasis-positive SLNs.

Design:

We have performed an updated meta-analysis of randomized controlled trials (RCTs) comparing SLNB alone or with RNI vs. ALND for early breast cancer patients with metastatic SLNs.

Data Sources and Methods:

Eligibility criteria included RCTs comparing SLNB ± RNI vs ALND for metastasis-positive SLN. PubMed, EMBASE, the Cochrane library, and online registers were searched for articles comparing SLNB alone vs. ALND for metastasis-positive SLN. Articles were evaluated for risk of bias using Cochrane’s revised tool (RoB). The main summary measures using the random effects model were hazard ratio and risk ratio.

Results:

Seven RCTs were included in the meta-analysis. Overall survival and DFS were superior in the SLNB group compared to the ALND group. Locoregional recurrence and mortality were comparable between both the groups. After stratifying RCTs with regards to adjuvant RNI, these parameters were still comparable to ALND.

Conclusion:

This meta-analysis suggests that SLNB, with or without RNI, offers comparable OS and DFS to ALND for early breast cancer patients with metastasis-positive SLNs. However, the inclusion of studies that did not differentiate between micrometastases and macrometastases may introduce bias, particularly when assessing the impact of RNI. The role of RNI remains debated specially in those with macrometastases, and future research should focus on stratified analyses to clarify this. While SLNB represents a viable alternative to ALND, further trials are needed to define the optimal role in subgroups with high-risk tumor biology.

Keywords

Breast cancer sentinel lymph node biopsy axillary lymph node dissection outcome randomized controlled trials meta-analysis

Introduction

Traditional management for early breast cancer patients with a clinically and radiologically node-negative axilla is sentinel lymph node biopsy (SLNB), followed by axillary lymph node dissection (ALND) in metastatic SLN.^1-4 Emerging evidence, including systematic reviews and meta-analyses, suggests that SLNB alone or with regional nodal irradiation (RNI) may suffice in carefully selected patients, sparing the potential complications of ALND (lymphedema, limited shoulder mobility, and neuropathic pain) without compromising oncological outcomes.^5-11

Owing to this, international guidelines recommended against the completion ALND in patients with metastatic SLN.^1,12,13 However, one of the reviews showed a statistically significant difference in locoregional recurrence (LRR) in favor of ALND.¹⁴ Hence, despite these recommendations, debates persist regarding the optimal management approach for patients with metastatic SLNs, particularly concerning the role of RNI in enhancing regional control and potentially improving survival outcomes. The need for a clear understanding of whether SLNB alone, SLNB with RNI, or ALND is preferable remains critical. Moreover, there is a lack of consensus on the effects of RNI in preventing recurrence when ALND is omitted, as well as its impact on long-term survival.

This study aims to address these gaps by conducting an updated meta-analysis of randomized controlled trials (RCTs) comparing SLNB with or without RNI against ALND in early-stage breast cancer patients with metastatic SLNs. By synthesizing the latest evidence, this analysis seeks to provide a comprehensive assessment of overall survival (OS), disease-free survival (DFS), LRR, and mortality outcomes, contributing valuable insights into the effectiveness and safety of SLNB as a potential alternative to ALND in specific patient populations.

Methods

Search strategy

The authors designed a priori search protocol (Supplementary document 1) to identify evidence relevant to this meta-analysis per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for updated systematic reviews¹⁵ (Supplementary file 2). MedLine (via PubMed), EMBASE, Cochrane library, online clinical trial registers, and websites (Clinicaltrials.gov, Ctri.nic.in) were reviewed from its inception till 30th April 2024. Reviewers (MMI, SA, and SKY) conducted the comprehensive electronic search (Appendix 1). Titles and abstracts were screened for eligibility by both reviewers. Full texts were retrieved after excluding irrelevant studies, duplicate studies, review articles, case reports, editorials, and letters to the editor/correspondences. After reading the full text, each article was coded as eligible, ineligible, or doubtful. All disagreements were resolved via discussion among all reviewers through online consultations.

Inclusion criteria

Study designs: RCTs

Participants: All patients of early breast cancer whose SLNB was positive for metastasis

Intervention: SLNB alone or with RNI

Comparator: Patients undergoing ALND after SLNB was positive for metastasis

Outcome: Primary outcome measures were OS and DFS. Secondary endpoints were LRR and death.

In case of multiple papers based on the same or overlapping data sets, then only the article with the most extended follow-up of patients was included

Exclusion criteria

Study designs: Prospective observation studies, case-control studies, review articles, case reports, editorials, and letters to the editor/correspondence

Participants: Studies not comparing SLNB/RNI vs ALND or studies that have used only one type and not compared the two groups

Outcome: Studies not providing required data of OS, DFS, LRR, and death

Quality assessment

The methodologic quality of included studies was assessed using Cochrane’s revised tool to assess the risk of bias in randomized trials (RoB 2 tool).¹⁶ Two reviewers evaluated individual bias items by assigning the above “Risk of bias” criteria as either “low,” “high,” or “unclear” risk.

Data extraction, analysis, and synthesis

Data extraction was carried out by the first author (MMI) and independently adjudicated by one other author (SKY) using a pilot data extraction form developed to address the research question. Disagreements were resolved by discussion among the reviewers. The extracted data included sample size, pathological definition of SLN metastasis, LRR, OS, DFS, and treatment regimens.

Statistical methods

Hazard ratio (HR) was used as a summary statistic for outcomes (OS and DFS). We calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI) for dichotomous outcomes. A statistically significant overall effect was defined as P ⩽ .05 or a 95% CI that did not cross the line of no effect (ie, 1 for RR).

Visual inspection of the forest plots and I² statistic, which quantifies inconsistency impacting meta-analysis, were used to describe heterogeneity. An I² statistic of 75% or more indicates a high degree of heterogeneity, and in such a situation, we did not pool data for meta-analysis.¹⁷

Data analysis was performed using the Cochrane Collaboration’s Review Manager Software (RevMan version 5.3). Publication bias was assessed by visual inspection of the funnel plot.

Level of evidence

The grading of recommendation, assessment, development, and evaluation (GRADE) instrument was used for recommendation strength in the included studies in the meta-analysis.^18,19 The quality of the evidence was characterized as high, moderate, low, or very low. The GRADE was assessed using an online tool from the website http://gradepro.org. Two review authors (SA and SKY) independently rated the quality of each outcome.

Results

As per our pre-defined criteria, seven articles were eligible for inclusion (Figure 1). All included studies were RCTs utilizing a parallel group non-inferiority design.^20-26 The AMAROS trial recently published a 10-year follow-up, which was included in this meta-analysis rather than this group’s previous publication.²¹ The characteristics of the included studies are listed in Table 1. A total of 7030 patients were included in the studies, 3585 in the SLNB/RNI group, and 3445 in the ALND group. The median duration of follow-up was 78.8 months (interquartile range 69.6 months). All studies reported outcomes directly comparing SLNB alone or with RNI vs ALND. Patients received postoperative adjuvant systemic therapy according to guidelines used at each center.

Figure 1.

PRISMA 2020 flow diagram for updated systematic reviews which included searches of databases, registers, and other sources.

Table 1.

Study characteristics.

Study/Characteristics	AATRM	ACOSOGZ0011	AMAROS	IBCSG	OTOASAR	SENOMAC	SINODAR
Single center/Multicentric	Multicentric	Multicentric	Multicentric	Multicentric	Single center	Multicentric	Multicentric
Sample size SLNB/ALND	119/108	436/420	602/672	453/447	230/244	1335/1205	410/403
Inclusion criteria	SLN + Micromets cT < 3.5 cm	1-2 SLN + Macromet & micromet cT < 5 cm	SLN + Macromet & micromet cT < 5 cm	SLN + Micromets cT < 5 cm	SLN + Macromet & micromet cT < 3.5 cm	1-2 SLN + Macromets cT1-3	1-2 SLN + Macromets cT < 5 cm
BCS/Mastectomy (SLNB)	Both 113 (93.34%)/8 (6.6%)	BCS	Both 557 (81.8%)/121 (17.8%)	Both 425 (90.7%)/42 (8.99%)	Both 200 (84%)/30 (16%)	Both 845 (63.3%)/490 (36.7%)	Both 333 (75.7%)/93 (21.1%) BCS mastectomy = 14 (3.2%)
BCS/Mastectomy (ALND)	Both 102 (91.1%)/10 (8.9%)	BCS	Both 609 (81.9%)/127 (17.1%)	Both 420 (90.5%)/44 (9.48%)	Both 200 (82%)/44 (18%)	Both 775 (64.3%)/430 (35.7%)	Both 328 (74.7%)/107 (24.4%) BCS mastectomy = 4 (0.9%)
SLNB micromets/macromets		164 (44.8%)/not mentioned	195 (25.8%)/419 (61.5%)		77 (33.5%)/139 (60.4%)	-/1LN = 1143 (85.6%), 2LN = 192 (14.4%)	3 (0.7%)/402 (91.4%)
ALND micromets/macromets		137 (37.5%)/115 (27.3%)	215 (28.9%)/442 (59.4%)		17 (7%)/77 (31.5%)	-/1LN = 1008 (83.7%), 2 LN = 197 (16.3%)	2 (0.5%)/403 (91.8%)
Follow-up duration	62 months (24-107 months)	111.6 months (9.3 years)	120 months (10 years)	116.4 months (9.7 years)	97 months (ALND), 95.6 months (SLNB)	46.8 months	34 months
LRR SLNB	3 (2.5%)	1 (0.2%)	26 (3.8%)	23 (5%) [local = 14 (3%), regional = 9 (2%)]	4 (1.7%)	18 (1.3%) [local = 12, regional = 6]	15 (3.4%)
LRR ALND	1 (1%)	0 (0%)	25 (3.4%)	16 (4%) [local = 13 (3%), regional = 3 (1%)]	5 (2%)	16 (1.3%) [local = 10, regional = 6]	11 (2.5%)
OS SLNB	-	86.30%	81.40%	90.80%	84.80%	92.90%	98.80%
OS ALND	-	83.60%	84.60%	88.20%	77.90%	92%	98.90%
DFS SLNB	97.47%	80.20%	70.10%	76.80%	77.40%	89.70%	95.60%
DFS ALND	99.07%	78.20%	75%	74.90%	72.10%	88.70%	96.40%
Adjuvant systemic therapy (SLNB)	CT = 42 (36.8%), CT + HT = 65 (57%), HT = 7 (6.2%)	423 (97%)	CT = 418 (61.3%), HT = 525 (77.1%), IT = 44 (6.4%)	CT = 32 (6.85%), HT = 315 (67.45%), CT + HT = 104 (22.26%)		529 (39.6%)	196 (44.6%)
Adjuvant systemic therapy (ALND)	CT = 41 (40.2%), CT + HT = 51 (50%), HT = 10 (9.8%)	402 (96%)	CT = 453 (60.9%), HT = 585 (78.6%), IT = 45 (6%)	CT = 41 (8.83%), HT = 292 (62.93%), CT + HT = 109 (23.49%)		496 (41.2%)	232 (52.9%)
Adjuvant radiotherapy (SLNB)	111 (93.3%)	277 (89.6%)	Breast/chest wall = 598 (87.8%), internal mammary chain = 65 (9.5%)	22 (5%)	230 (100%)	1192 (89.9%)
Adjuvant radiotherapy (ALND)	98 (90.7%)	263 (88.9%)	Breast/chest wall = 632 (84.9%), internal mammary chain = 72 (9.7%)	20 (4%)	0 (0%)	1058 (88.4%)
Extra remarks	SLN metastasis < 1 mm and > 1 mm data givenSystemic adjuvant therapy data splitted mode of therapy wise	% of radiation therapy received does not match with total patients in the group	Adjuvant therapy data splitted	BCS/mastectomy/adjuvant % (with 467 in SLNB and 464 in ALND)SLN metastasis < 1 mm and > 1 mm data given		Micromets not mentioned	Radiotherapy data not split between two groups

Risk of bias assessment

Each risk of bias item for individual studies and across all studies are depicted in Figures 2 and 3. Three studies did not report methods for random sequence generation and were rated as high risk of bias,^21-23 three had an unclear risk of bias,^20,21,25 and one had a low risk of bias.²⁶ All studies had unclear risk of bias for allocation concealment ^20-22,25,26 except IBCSG (no risk) and OTOASAR (high risk). All studies had a low risk of bias for blinding participants except SENOMAC and SINODAR (high risk). All studies had a low risk of bias for other parameters.

Figure 2.

Risk of bias graph: each risk of bias item presented as percentages across all included studies.

Figure 3.

Risk of bias summary: each risk of bias item for individual studies.

Meta-analysis of primary outcomes

Five trials provided data to calculate the HR. Overall HR for death was 0.84 (95% CI: 0.73-0.97, P = .01), suggesting OS was superior in the SLNB group (Figure 4A). The heterogeneity (I²) was 0%, indicating low heterogeneity. Sensitivity analysis was conducted to assess the effect of each RCT on the OS, and it showed that the results were the same, ie, OS was superior in the SLNB group (the highest P-value was .05 after removing OTOASAR RCT). We also analyzed HR for OS based on further axillary treatment in the SLNB arm with or without adjuvant RNI. The SENOMAC trial did not provide adjuvant RNI data; hence, it was excluded. On stratifying RCTs with SLNB alone (no RNI) vs ALND (ACOSOGZ0011 and IBCSG), OS was still superior in SLNB alone group but statistically non-significant (HR 0.85, 95% CI 0.68-1.06, P = .14) (Figure 4B). Adjuvant RNI to axilla was given in two studies (AMAROS and OTOASAR), and although non-significant, OS was superior in the SLNB + RNI group as compared with ALND (HR 0.76, 95% CI 0.57-1.07, P = .11) (Figure 4C).

Figure 4.

Forest plot for overall survival (A) overall SLNB group vs ALND, (B) SLNB alone vs ALND, and (C) SLNB + RT vs ALND.

Five trials were included in DFS synthesis as they provided sufficient data to pool the results. Overall HR for death was 0.85 (95% CI: 0.74-0.97, P = .02, (I²) = 0%.), suggesting DFS was superior in the SLNB group (Figure 5A). The sensitivity analysis conducted to assess the effect of each trial showed that if AMAROS trial is excluded from the analysis, results are rendered nonsignificant (P = .10). Similarly, we analyzed HR for DFS based on whether adjuvant RNI was given after SLNB or not in the experimental arm. Again, the SENOMAC trial did not provide adjuvant RNI data; hence, it was excluded. On stratifying RCTs with SLNB alone (no RNI) vs ALND (ACOSOGZ0011 and IBCSG), DFS was still superior in SLNB alone group but statistically non-significant (HR 0.85, 95% CI 0.68-1.06, P = .17) (Figure 5B). Adjuvant RNI to axilla was given in two studies (AMAROS and OTOASAR), although non-significant, OS was superior in SLNB + RNI group as compared with ALND (HR 0.84, 95% CI 0.68-1.02, P = .08) (Figure 5C).

Figure 5.

Forest plot for disease free survival (A) overall SLNB group vs ALND, (B) SLNB alone vs ALND, and (C) SLNB with RT vs ALND.

Meta-analysis of secondary outcomes

Seven studies were included in the meta-analysis of LRR, and it was slightly higher in the SLNB group. The overall RR was 1.18 (95% CI 0.87-1.60), but it was not significant (P = .29, (I²) = 0%.) (Figure 6A). In the sensitivity analysis, omission of any RCT did not render the results statistically significant. Similar to OS and DFS, we analyzed trials based on SLNB alone vs ALND (AATRM, ACOSOGZ0011, IBCSG, and SINODAR) and SLNB + RNI vs ALND (AMAROS and OTOASAR) (Figure 6B and C). The SENOMAC trial was excluded as it did not provide RNI data. Sentinel lymph node biopsy alone and SLNB + RT both had similar LRRs to those of ALND.

Figure 6.

Forest plot for locoregional recurrence (A) overall SLNB group vs ALND, (B) SLNB alone vs ALND, and (C) SLNB with RT vs ALND.

Six studies were included in the meta-analysis of mortality (the total number of deceased patients per trial). The AATRM trial was excluded as it did not provide mortality data. Mortality was higher in the ALND group, but it was not significant statistically (RR 0.90, 95% CI 0.77-1.04, P = .15, (I²) = 0%.) (Figure 7A). The exclusion of the AMAROS trial renders the RR (0.80, 95% CI 0.67-0.97) statistically significant with a P-value equal to .02. We analyzed trials based on SLNB alone vs ALND (ACOSOGZ0011, IBCSG and SINODAR) and SLNB + RNI vs ALND (AMAROS and OTOASAR) (Figure 7B and C). The SENOMAC trial was excluded as it did not provide RNI data. Sentinel lymph node biopsy alone and SLNB + RNI both had similar mortality compared with ALND.

Figure 7.

Forest plot for mortality (A) overall SLNB group vs ALND, (B) SLNB alone vs ALND, and (C) SLNB with RT vs ALND.

Visual inspection of the funnel plot did not reveal any publication bias (Figure 8). Overall, the quality of the evidence from the outcomes evaluated by the GRADE system was high for OS, DFS, LRR, and mortality, suggesting high confidence in the estimated effect from the assessed outcomes (Table 2).

Figure 8.

Funnel plot.

Table 2.

GRADE assessment.

Certainty assessment							Effect		Certainty	Importance
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Relative(95% CI)	Absolute(95% CI)	Certainty	Importance
5	Randomized trials	Not serious	Not serious	Not serious	Not serious	None	HR 0.84(0.73-0.97)	1 fewer per 1000 (from 1 fewer to 1 fewer)	⨁⨁⨁⨁High
5	Randomized trials	Not serious	Not serious	Not serious	Not serious	None	HR 0.85(0.74-0.99)	1 fewer per 1000 (from 1 fewer to 1 fewer)	⨁⨁⨁⨁High
7	Randomized trials	Not serious	Not serious	Not serious	Not serious	None	RR 1.18(0.87-1.60)	4 more per 1000 (from 3 fewer to 13 more)	⨁⨁⨁⨁High
6	Randomized trials	Not serious	Not serious	Not serious	Not serious	None	RR 0.90(0.77-1.04)	10 fewer per 1000 (from 22 fewer to 4 more)	⨁⨁⨁⨁High

CI: confidence interval; HR: hazard ratio; RR: risk ratio.

Discussion

Our updated systematic review and meta-analysis confirms that SLNB is associated with superior OS and DFS compared to ALND, with no significant difference in LRR between the two groups. This updated analysis further reveals that OS, DFS, LRR, and mortality outcomes are comparable to ALND, even when adjuvant regional node irradiation (RNI) is not administered.

Systematic reviews and meta-analyses are essential tools an essential tool in evidence-based medicine as they identify, select, appraise, and synthesize evidence from relevant studies on a particular topic. By including all available evidence, it provides a more comprehensive understanding of the research landscape compared with individual studies. Meta-analysis, a component of systematic review, statistically combines data from multiple studies to provide a more precise estimate of the effect size which enhances the statistical power of the findings. In addition, systematic reviews reveal gaps in existing research thereby highlighting areas where further investigation is needed. This helps guide future research priorities and clinical practice.

In the last couple of decades, the standard axillary management of early breast cancer has evolved, and SLNB has replaced ALND for the treatment of clinically node-negative axilla.²⁷ The concept of further de-escalation of axillary surgery in metastatic SLN was first introduced widely by milestone RCT of the American College of Surgeons Oncology Group (ACOSOG) Z0011).²¹ After the ACOSOGZ0011 trial, several other trials showed improved OS and DFS with SLNB ± RNI compared with ALND in early-stage breast cancer.^20,22-26 As expected, locoregional standards for axillary management became the hottest research topic, and multiple meta-analyses were performed.^8,11,28-33 Some of these could not provide conclusive recommendations as they were based on limited RCTs.^2-4,28-32 Meta-analysis by Peristeri and Harissis¹⁴ included five RCTs and provided high-strength evidence that SLNB was associated with better OS and DFS. However, they also reported an increased risk of LRR with SLNB; similar results were found by other systematic reviews and meta-analyses.^8-10 However, these studies included prospective cohort and retrospective studies as well, thereby introducing the possibility of selection biases and heterogeneity, Our updated meta-analysis employed a more rigorous methodology (inclusion of only RCTs), comprehensive search strategy (including two latest RCTs and updated results of a previous trial), and assessment for the strength of the evidence (by GRADE assessment). We have also analyzed data for SLNB alone and SLNB + RNI vs. ALND, as sufficient number of trials were available. Our analysis suggests that ALND can be safely omitted in patients with limited SLN metastasis, defined variably across studies as either micrometastases or macrometastases up to 1 to 2 positive sentinel lymph nodes. Given these differences in inclusion criteria, further research is needed to refine patient selection criteria for axillary de-escalation.

The selection of patients for the omission of ALND is debatable. The high-risk groups like triple-negative, HER2 positives, SLN with extracapsular extension and cT2 breast cancer patients were underrepresented in all trials except SENOMAC. In addition, although all except the Z0011 trial have included mastectomy, the number of patients with mastectomy was significantly less compared with BCS. The radiotherapy nodal targets were not explicit in Z0011, and in SENOMAC, 89.9% had nodal RT in the SLNB group. The awaited result of POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy (POSNOC) RCT may help physicians in objectively selecting patients for axillary de-escalation (observation vs RT) in SLN-positive early breast cancer patients.³⁴

The major limitations of our meta-analysis were the limited number of RCTs, some of which have short follow-up periods as delayed recurrences are common in breast cancer. However, an updated follow-up of 10 years of AMAROS trial favors the SLNB group.¹⁵ Another limitation is that these studies should have reported pathologists’ experience and detailed pathological evaluation techniques. Diagnosis of metastasis is increased with experienced pathologists, and hence, our research findings may not be applicable in settings where this is lacking. Another key limitation is the inclusion of studies that did not distinguish between micrometastases and macrometastases in positive sentinel lymph nodes. This is particularly relevant when assessing the impact of RNI, as its benefit remains unclear for patients with macrometastases. Finally, the underrepresentation of certain high-risk patient subgroups, such as those with HER2-positive or triple-negative breast cancer, extracapsular extension, or larger tumors, limits the generalizability of our findings.

While our study suggests that RNI may serve as an alternative to ALND in selected cases, our meta-analysis did not demonstrate a statistically significant survival advantage with RNI. Further research is needed to better define the role of RNI in patients with positive SLNs who forego ALND. Future research could explore whether certain subgroups benefit more from RNI than others. Additional long-term studies focusing on patient-reported outcomes, such as quality of life, functional outcomes, and lymphedema rates, are essential. Such research would provide a more comprehensive understanding of the real-world impact of these approaches and could further inform patient-centered care decisions. Further trials to address high-risk subgroups such as patients with triple-negative breast cancer, HER2-positive tumors, and those with larger tumors or extracapsular extension remain underrepresented in trials. Targeted trials are needed to evaluate the safety and efficacy of omitting ALND in these subpopulations.

Conclusion

This meta-analysis suggests that SLNB, with or without RNI, offers comparable OS and DFS to ALND for early breast cancer patients with metastasis-positive SLNs. However, the inclusion of studies that did not differentiate between micrometastases and macrometastases may introduce bias, particularly when assessing the impact of RNI. Role of RNI remains debated specially in those with macrometastases, and future research should focus on stratified analyses to clarify this. While SLNB represents a viable alternative to ALND, further trials are needed to define the optimal role in subgroups with high-risk tumor biology.

Supplemental Material

sj-docx-1-bcb-10.1177_11782234251335409 – Supplemental material for Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection for Early-Stage Breast Cancer and Sentinel Lymph Node Metastasis: An Updated Systematic Review and Meta-Analysis With Special Focus on Locoregional Recurrence and Regional Node Irradiation

Supplemental material, sj-docx-1-bcb-10.1177_11782234251335409 for Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection for Early-Stage Breast Cancer and Sentinel Lymph Node Metastasis: An Updated Systematic Review and Meta-Analysis With Special Focus on Locoregional Recurrence and Regional Node Irradiation by Sanjit Kumar Agrawal, M. Mohammed Imran, Shivank Sethi, Sanjay Kumar Yadav, Pawan Agarwal and Dhananjaya Sharma in Breast Cancer: Basic and Clinical Research

Supplemental Material

sj-docx-2-bcb-10.1177_11782234251335409 – Supplemental material for Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection for Early-Stage Breast Cancer and Sentinel Lymph Node Metastasis: An Updated Systematic Review and Meta-Analysis With Special Focus on Locoregional Recurrence and Regional Node Irradiation

Supplemental material, sj-docx-2-bcb-10.1177_11782234251335409 for Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection for Early-Stage Breast Cancer and Sentinel Lymph Node Metastasis: An Updated Systematic Review and Meta-Analysis With Special Focus on Locoregional Recurrence and Regional Node Irradiation by Sanjit Kumar Agrawal, M. Mohammed Imran, Shivank Sethi, Sanjay Kumar Yadav, Pawan Agarwal and Dhananjaya Sharma in Breast Cancer: Basic and Clinical Research

Footnotes

Appendix 1 ORCID iD

Sanjay Kumar Yadav

Ethical Considerations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional ethical approval was not applicable.

Consent for Publication

Not applicable

Author Contributions

Sanjit Kumar Agrawal: Conceptualization; Investigation; Methodology; Validation; Visualization; Writing—original draft; Writing—review & editing.

M. Mohammed Imran: Data curation; Writing—review & editing.

Shivank Sethi: Data curation; Writing—original draft; Writing—review & editing.

Sanjay Kumar Yadav: Conceptualization; Data curation; Formal analysis; Methodology; Project administration; Resources; Software; Validation; Writing—original draft; Writing—review & editing.

Pawan Agarwal: Writing—original draft; Writing—review & editing.

Dhananjaya Sharma: Writing—original draft; Writing—review & editing.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

Data may be accessed upon reasonable request to the corresponding author.

Supplemental Material

Supplemental material for this article is available online.

References

National Comprehensive Cancer Network (NCCN) for Patients with Invasive Breast Cancer. Accessed December 20, 2023. https://www.nccn.org/patients/guidelines/content/PDF/breast-invasive-patient.pdf

Pepels

Vestjens

de Boer

, et al. Safety of avoiding routine use of axillary dissection in early-stage breast cancer: a systematic review. Breast Cancer Res Treat. 2011;125:301-313.

Cox

Kiluk

Riker

, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg. 2008;206:261-268.

Hwang

Gonzalez-Angulo

, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110:723-730.

Lee

Choi

Kim

, et al. Comparative study between sentinel lymph node biopsy and axillary dissection in patients with one or two lymph node metastases. J Breast Cancer. 2018;21:306-314.

Nayyar

Strassle

Shen

Black

Gallagher

McGuire

KP.

Survival analysis of early-stage breast cancer patients undergoing axillary lymph node dissection and sentinel lymph node dissection. Am J Surg. 2018;216:706-712.

Donker

van Tienhoven

Straver

, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomized, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303-1310.

Gao

Zeng

, et al. Axilla lymph node dissection can be safely omitted in patients with 1–2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis. Breast Cancer Res Treat. 2022;196:129-141.

Zhang

, et al. Axillary management in patients with clinical node-negative early breast cancer and positive sentinel lymph node: a systematic review and meta-analysis. Front Oncol. 2024;13:1320867.

10.

Heiranizadeh

Rafiei Shahamabadi

Dehghan

, et al. Comparing early-stage breast cancer patients with sentinel lymph node metastasis with and without completion axillary lymph node dissection: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2022;23:2561-2571.

11.

Chen

Lin

, et al. Can axillary lymph node dissection be omitted in breast cancer patients with metastatic sentinel lymph nodes undergoing mastectomy? a systematic review and meta-analysis of real-world evidence. World J Surg. 2023;47:2446-2456.

12.

Brackstone

, et al. Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO guideline. J Clin Oncol. 2021;39:3056-3082.

13.

Loibl

André

Bachelot

, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159-182.

14.

Peristeri

Harissis

HV.

Axillary lymph node dissection vs sentinel biopsy only among women with early-stage breast cancer and sentinel node metastasis: a systematic review and meta-analysis. Breast J. 2021;27:158-164.

15.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

16.

Sterne

JAC

Savović

Page

, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898.

17.

Higgins

Thompson

Deeks

Altman

DG.

Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.

18.

Balshem

Helfand

Schünemann

, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401-406.

19.

Schünemann

Brozek

Oxman

, eds. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 [updated March 2009]. The GRADE Working Group; 2009. Accessed April 10, 2025. http://www.cc-ims.net/gradepro

20.

Solá

Alberro

Fraile

, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20:120-127.

21.

Giuliano

Ballman

McCall

, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 randomized clinical trial. JAMA. 2017;318:918-926.

22.

Bartels

SAL

Donker

Poncet

, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41:2159-2165.

23.

Galimberti

Cole

Viale

, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases: 10-year follow-up of a randomized, controlled phase 3 trial. Lancet Oncol. 2018;19:1385-1393.

24.

Sávolt

Péley

Polgár

, et al. Eight—year follow—up result of the OTOASOR trial: the optimal treatment of the axilla—surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. Eur J Surg Oncol. 2017;43:672-679.

25.

de Boniface

Filtenborg Tvedskov

Rydén

, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163-1175.

26.

Tinterri

Gentile

Gatzemeier

, et al. Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29:5732-5744.

27.

Giuliano

Kirgan

Guenther

Morton

DL.

Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer [published correction appears in J Clin Oncol 2000 Nov 15;18(22):3877]. J Clin Oncol. 2000;18:2553-2559. doi:10.1200/JCO.2000.18.13.2553.

28.

Glechner

Wöckel

Gartlehner

, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49:812-825. doi:10.1016/j.ejca.2012.09.010.

29.

Zhang

Zhu

HC.

Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41:958-966. doi:10.1016/j.ejso.2015.05.007.

30.

Huang

Kuo

Chen

, et al. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: a systematic review and meta-analysis of randomized controlled trials using the GRADE system. Int J Surg. 2016;34:73-80. doi:10.1016/j.ijsu.2016.08.022.

31.

Ram

Singh

McCaig

Sentinel node biopsy alone versus completion axillary node dissection in node-positive breast cancer: systematic review and meta-analysis. Int J Breast Cancer. 2014;2014:513780. doi:10.1155/2014/469803.

32.

Zhang

Wang

Axillary radiotherapy: an alternative treatment option for adjuvant axillary management of breast cancer. Sci Rep. 2016;6:26304. doi:10.1038/srep26304.

33.

Petousis

Christidis

Margioula-Siarkou

, et al. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2022;306:1221-1234. doi:10.1007/s00404-022-06458-8.

34.

Goyal

Mann

Fallowfield

, et al. POSNOC Trialists. POSNOC—POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open. 2021;11:e054365. doi:10.1136/bmjopen-2021-054365.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB